

119TH CONGRESS
2D SESSION

H. R. 1266

[Report No. 119–]

To prohibit certain uses of xylazine, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

FEBRUARY 12, 2025

Mr. PANETTA (for himself, Mr. PFLUGER, Mr. BILIRAKIS, Mr. PAPPAS, Mr. FITZGERALD, Ms. ROSS, Mr. CRENSHAW, Mr. HARDER of California, Ms. DELBENE, Mrs. MILLER-MEEKS, Ms. PETTERSEN, Ms. CLARKE of New York, Mr. DELUZIO, Mr. MAGAZINER, Mr. BACON, Mr. OBERNOLTE, Mr. COSTA, Mr. BALDERSON, Ms. BARRAGÁN, Mr. CISCOMANI, Mr. CAREY, Mrs. BICE, Ms. CRAIG, Mr. NORCROSS, Mr. FONG, Ms. TENNEY, Mr. FITZPATRICK, Mr. BURCHETT, Ms. DEAN of Pennsylvania, Mr. COHEN, Mr. DAVIS of North Carolina, Mr. CORREA, Mr. WEBSTER of Florida, Mr. COLLINS, Mr. SUOZZI, and Mrs. HARSHBARGER) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

SEPTEMBER --, 2026

Reported from the Committee on Energy and Commerce with an amendment

[Strike out all after the enacting clause and insert the part printed in *italie*]

[For text of introduced bill, see copy of bill as introduced on February 12, 2025]

A BILL

To prohibit certain uses of xylazine, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 *This Act may be cited as the “Combating Illicit*
5 *Xylazine Act”.*

6 **SEC. 2. DEFINITIONS.**

7 (a) *IN GENERAL.*—*In this Act, the term “xylazine”*
8 *has the meaning given the term in paragraph (61) of sec-*
9 *tion 102 of the Controlled Substances Act, as added by sub-*
10 *section (b) of this section.*

11 (b) *CONTROLLED SUBSTANCES ACT.*—*Section 102 of*
12 *the Controlled Substances Act (21 U.S.C. 802) is amended*
13 *by adding at the end the following:*

14 “(61) *The term ‘xylazine’ means the substance*
15 *xylazine, including its salts, isomers, and salts of isomers*
16 *whenever the existence of such salts, isomers, and salts of*
17 *isomers is possible.”.*

18 **SEC. 3. ADDING XYLAZINE TO SCHEDULE III.**

19 *Schedule III of section 202(c) of the Controlled Sub-*
20 *stances Act (21 U.S.C. 812) is amended by adding at the*
21 *end the following:*

22 “(f) *Unless specifically excepted or unless listed in an-*
23 *other schedule, any material, compound, mixture, or prepa-*
24 *ration which contains any quantity of xylazine.”.*

1 **SEC. 4. AMENDMENTS.**

2 (a) *AMENDMENT.*—Section 102 of the Controlled Sub-
3 stances Act (21 U.S.C. 802) is amended by striking para-
4 graph (27) and inserting the following:

5 “(27)(A) *Except as provided in subparagraph (B), the*
6 *term ‘ultimate user’ means a person who has lawfully ob-*
7 *tained, and who possesses, a controlled substance for the use*
8 *by the person or for the use of a member of the household*
9 *of the person or for an animal owned by the person or by*
10 *a member of the household of the person.*

11 “(B)(i) *In the case of xylazine, other than for a drug*
12 *product approved under subsection (b) or (j) of section 505*
13 *of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.*
14 *355), the term ‘ultimate user’ means a person—*

15 “(I) *to whom xylazine was dispensed by—*

16 “(aa) *a veterinarian registered under this*
17 *Act; or*

18 “(bb) *a pharmacy registered under this Act*
19 *pursuant to a prescription of a veterinarian reg-*
20 *istered under this Act; and*

21 “(II) *who possesses xylazine for—*

22 “(aa) *an animal owned by the person or by*
23 *a member of the household of the person;*

24 “(bb) *an animal under the care of the per-*
25 *son;*

1 “(cc) use in government animal-control pro-
2 grams authorized under applicable Federal,
3 State, Tribal, or local law; or

4 “(dd) use in wildlife programs authorized
5 under applicable Federal, State, Tribal, or local
6 law.

7 “(ii) In this subparagraph, the term ‘person’ in-
8 cludes—

9 “(I) a government agency or business where ani-
10 mals are located; and

11 “(II) an employee or agent of an agency or busi-
12 ness acting within the scope of their employment or
13 agency.”.

14 (b) *FACILITIES.*—An entity that manufactures
15 xylazine, as of the date of enactment of this Act, shall not
16 be required to make capital expenditures necessary to in-
17 stall the security standard required of schedule III of the
18 Controlled Substances Act (21 U.S.C. 801 et seq.) for the
19 purposes of manufacturing xylazine.

20 (c) *LABELING.*—The requirements related to labeling,
21 packaging, and distribution logistics of a controlled sub-
22 stance in schedule III of section 202(c) of the Controlled
23 Substances Act (21 U.S.C. 812(c)) shall not take effect for
24 xylazine until the date that is 1 year after the date of enact-
25 ment of this Act.

1 (d) *PRACTITIONER REGISTRATION.*—*The requirements*
2 *related to practitioner registration, inventory, and record-*
3 *keeping of a controlled substance in schedule III of section*
4 *202(c) of the Controlled Substances Act (21 U.S.C. 812(c))*
5 *shall not take effect for xylazine until the date that is 60*
6 *days after the date of enactment of this Act. A practitioner*
7 *that has applied for registration during the 60-day period*
8 *beginning on the date of enactment of this Act may continue*
9 *their lawful activities until such application is approved*
10 *or denied.*

11 (e) *MANUFACTURER TRANSITION.*—*The Food and*
12 *Drug Administration and the Drug Enforcement Adminis-*
13 *tration shall facilitate and expedite the relevant manufac-*
14 *turer submissions or applications required by the placement*
15 *of xylazine on schedule III of section 202(c) of the Con-*
16 *trolled Substances Act (21 U.S.C. 812(c)).*

17 (f) *CLARIFICATION.*—*Nothing in this Act, or the*
18 *amendments made by this Act, shall be construed to require*
19 *the registration of an ultimate user of xylazine under the*
20 *Controlled Substances Act (21 U.S.C. 801 et seq.) in order*
21 *to possess xylazine in accordance with subparagraph (B)*
22 *of section 102(27) of that Act (21 U.S.C. 802(27)), as added*
23 *by subsection (a) of this section.*

1 **SEC. 5. ARCOS TRACKING.**

2 *Section 307(i) of the Controlled Substances Act (21*
3 *U.S.C. 827(i)) is amended—*

4 *(1) in the matter preceding paragraph (1)—*

5 *(A) by inserting “or xylazine” after*
6 *“gamma hydroxybutyric acid”;*

7 *(B) by inserting “or 512” after “section*
8 *505”; and*

9 *(C) by inserting “respectively,” after “the*
10 *Federal Food, Drug, and Cosmetic Act,”; and*

11 *(2) in paragraph (6), by inserting “or xylazine”*
12 *after “gamma hydroxybutyric acid”.*

13 **SEC. 6. SENTENCING COMMISSION.**

14 *Pursuant to its authority under section 994(p) of title*
15 *28, United States Code, the United States Sentencing Com-*
16 *mission shall review and, if appropriate, amend its sen-*
17 *tencing guidelines, policy statements, and official com-*
18 *mentary applicable to persons convicted of an offense under*
19 *section 401 of the Controlled Substances Act (21 U.S.C.*
20 *841) or section 1010 of the Controlled Substances Import*
21 *and Export Act (21 U.S.C. 960) to provide appropriate*
22 *penalties for offenses involving xylazine that are consistent*
23 *with the amendments made by this Act. In carrying out*
24 *this section, the Commission should consider the common*
25 *forms of xylazine as well as its use alongside other scheduled*
26 *substances.*

1 **SEC. 7. REPORT TO CONGRESS ON XYLAZINE.**

2 (a) *INITIAL REPORT.*—Not later than 18 months after
3 the date of the enactment of this Act, the Attorney General,
4 acting through the Administrator of the Drug Enforcement
5 Administration and in coordination with the Commissioner
6 of Food and Drugs, shall submit to Congress a report on
7 the prevalence of illicit use of xylazine in the United States
8 and the impacts of such use, including—

9 (1) where the drug is being diverted;

10 (2) where the drug is originating; and

11 (3) whether any analogues to xylazine, or related
12 or derivative substances, exist and present a substan-
13 tial risk of abuse.

14 (b) *ADDITIONAL REPORT.*—Not later than 4 years
15 after the date of the enactment of this Act, the Attorney
16 General, acting through the Administrator of the Drug En-
17 forcement Administration and in coordination with the
18 Commissioner of Food and Drugs, shall submit to Congress
19 a report updating Congress on the prevalence and prolifera-
20 tion of xylazine trafficking and misuse in the United States.